CONFERENCE ON RETROVIRUSES
AND OPPORTUNISTIC INFECTIONS

Boston, Massachusetts
March 8–11, 2020

 

CROI 2019 Media Highlights

test

Below is a selection of coverage from studies that generated significant media attention at the 2019 Conference on Retroviruses and Opportunistic Infections (CROI). You may also wish to visit the Press Conference Webcasts page for discussions on key sessions at CROI 2019.

Note: The indication LB beside some abstract numbers below indicated a late-breaking abstract which represent studies of data analyzed after the general abstract submission deadline which also meet a high threshold of scientific merit.

29 LB SUSTAINED HIV-1 REMISSION FOLLOWING HOMOZYGOUS CCR5 DELTA32 ALLOGENIC HSCT

Presenting Author: Ravindra Gupta, University College London, London, UK

39 LB RANDOMIZED TRIAL OF RALTEGRAVIR-ART VS EFAVIRENZ-ART WHEN INITIATED DURING PREGNANCY

Presenting Author: Mark Mirochnick, Boston University, Boston, MA, US

40 LB RCT OF DOLUTEGRAVIR VS EFAVIRENZ-BASED THERAPY INITIATED IN LATE PREGNANCY: DOLPHIN-2

Presenting Author: Saye Khoo, University of Liverpool, Liverpool, UK

47 INCIDENT SYPHILIS RATES AND PREDICTORS IN US WOMEN WITH HIV, 2005-2016

Presenting Author: Jodie Dionne-Odom, University of Alabama at Birmingham, Birmingham, AL, US

53 LB POINT-OF-CARE VIRAL LOAD TESTING IMPROVES HIV VIRAL SUPPRESSION AND RETENTION IN CARE

Presenting Author: Paul Drain, University of Washington, Seattle, WA, US

80 LB SAFETY & PK OF WEEKLY RIFAPENTINE/ISONIAZID (3HP) IN ADULTS WITH HIV ON DOLUTEGRAVIR

Presenting Author: Kelly Dooley, Johns Hopkins University School of Medicine, Baltimore, MD, US

92 LB IMPACT OF UNIVERSAL TESTING AND TREATMENT IN ZAMBIA AND SOUTH AFRICA: HPTN071 (POPART)

Presenting Author: Richard Hayes, London School of Hygiene & Tropical Medicine, London, UK

104 LB THE PHASE 3 DISCOVER STUDY: DAILY F/TAF OR F/TDF FOR HIV PREEXPOSURE PROPHYLAXIS

Presenting Author: Charles Hare, University of California San Francisco, San Francisco, CA, US

139 LONG-ACTING CABOTEGRAVIR + RILPIVIRINE AS MAINTENANCE THERAPY: ATLAS WEEK 48 RESULTS

Presenting Author: Susan Swindells, University of Nebraska Medical Center, Omaha, NE, US